Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties.

Kim IH, Tsai HJ, Nishi K, Kasagami T, Morisseau C, Hammock BD.

J Med Chem. 2007 Oct 18;50(21):5217-26. Epub 2007 Sep 26.

2.

Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation.

Hutchens MP, Nakano T, Dunlap J, Traystman RJ, Hurn PD, Alkayed NJ.

Resuscitation. 2008 Jan;76(1):89-94. Epub 2007 Aug 28.

3.

Orally bioavailable potent soluble epoxide hydrolase inhibitors.

Hwang SH, Tsai HJ, Liu JY, Morisseau C, Hammock BD.

J Med Chem. 2007 Aug 9;50(16):3825-40. Epub 2007 Jul 6.

4.

Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo.

Ai D, Fu Y, Guo D, Tanaka H, Wang N, Tang C, Hammock BD, Shyy JY, Zhu Y.

Proc Natl Acad Sci U S A. 2007 May 22;104(21):9018-23. Epub 2007 May 10.

5.

Soluble epoxide hydrolase: a novel therapeutic target in stroke.

Zhang W, Koerner IP, Noppens R, Grafe M, Tsai HJ, Morisseau C, Luria A, Hammock BD, Falck JR, Alkayed NJ.

J Cereb Blood Flow Metab. 2007 Dec;27(12):1931-40. Epub 2007 Apr 18.

6.

Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase.

Loch D, Hoey A, Morisseau C, Hammock BO, Brown L.

Cell Biochem Biophys. 2007;47(1):87-98.

7.

Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors.

Campbell WB, Falck JR.

Hypertension. 2007 Mar;49(3):590-6. Epub 2007 Jan 2. Review.

8.

Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury.

Seubert JM, Zeldin DC, Nithipatikom K, Gross GJ.

Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):50-9. Epub 2006 Jul 10. Review.

9.

Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice.

Luria A, Weldon SM, Kabcenell AK, Ingraham RH, Matera D, Jiang H, Gill R, Morisseau C, Newman JW, Hammock BD.

J Biol Chem. 2007 Feb 2;282(5):2891-8. Epub 2006 Nov 29.

10.

Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors.

Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai HJ, Kim IH, Tuteja D, Mateo RK, Singapuri A, Davis BB, Low R, Hammock BD, Chiamvimonvat N.

Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18733-8. Epub 2006 Nov 27.

11.

Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase.

Kim IH, Nishi K, Tsai HJ, Bradford T, Koda Y, Watanabe T, Morisseau C, Blanchfield J, Toth I, Hammock BD.

Bioorg Med Chem. 2007 Jan 1;15(1):312-23. Epub 2006 Sep 29.

12.

Action of epoxyeicosatrienoic acids on cellular function.

Spector AA, Norris AW.

Am J Physiol Cell Physiol. 2007 Mar;292(3):C996-1012. Epub 2006 Sep 20. Review.

13.

Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function.

Seubert JM, Sinal CJ, Graves J, DeGraff LM, Bradbury JA, Lee CR, Goralski K, Carey MA, Luria A, Newman JW, Hammock BD, Falck JR, Roberts H, Rockman HA, Murphy E, Zeldin DC.

Circ Res. 2006 Aug 18;99(4):442-50. Epub 2006 Jul 20.

14.

Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling.

Pokreisz P, Fleming I, Kiss L, Barbosa-Sicard E, Fisslthaler B, Falck JR, Hammock BD, Kim IH, Szelid Z, Vermeersch P, Gillijns H, Pellens M, Grimminger F, van Zonneveld AJ, Collen D, Busse R, Janssens S.

Hypertension. 2006 Apr;47(4):762-70. Epub 2006 Feb 27.

15.
16.

The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase.

Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, Zhu Y, Spector AA, Gill S, Morisseau C, Hammock BD, Shyy JY.

Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16747-52. Epub 2005 Nov 2.

17.

An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension.

Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, Kim IH, Watanabe T, Hammock BD.

Hypertension. 2005 Oct;46(4):975-81. Epub 2005 Sep 12.

18.

Soluble epoxide hydrolase is a therapeutic target for acute inflammation.

Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, Hammock BD.

Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9772-7. Epub 2005 Jun 30.

19.

Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension.

Jung O, Brandes RP, Kim IH, Schweda F, Schmidt R, Hammock BD, Busse R, Fleming I.

Hypertension. 2005 Apr;45(4):759-65. Epub 2005 Feb 7.

20.

Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor.

Smith KR, Pinkerton KE, Watanabe T, Pedersen TL, Ma SJ, Hammock BD.

Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2186-91. Epub 2005 Jan 31.

Supplemental Content

Support Center